Tests a stem cell gene therapy in adults with newly diagnosed glioblastoma
Tests MSC11FCD, a modified stem cell therapy, in adults with newly diagnosed glioblastoma.
Key facts
- Who runs it
- CHA University
- Where
- Seongnam, South KoreaSee the site
- Trial code
- Registry title
- A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 10 people, planned
- Started
- 23 Oct 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Treatments tested
- MSC11FCD
- Record updated
- 22 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 19 to 70 with newly diagnosed glioblastoma, a brain tumour. It tests the safety of a stem cell therapy given into the tumour after surgery.
- Age
- 19 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed glioblastoma, confirmed by medical imaging after standard glioblastoma therapy. Expected survival of at least 3 months.
- Earlier treatment
- People who have had standard therapy for glioblastoma can join. People who have had any other type of immunotherapy cannot join.
Main reasons for not taking part
- Recurrent glioblastoma
- Known DPD deficiency, or allergy to flucytosine (5-FC) or 5-fluorouracil (5-FU)
- Gliadel wafer implanted during surgery
- Another cancer now or in the past 5 years
- Pregnant or breastfeeding women, or those planning pregnancy
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Patients aged 19 to 70
- Patients diagnosed with newly diagnosed glioblastoma based on medical imaging after receiving standard therapy for glioblastoma
- Patients whose expected survival period is at least 3 months
- Patients who have not received any other types of immunotherapy
- Patients who have been given a sufficient explanation of the purpose and details of the clinical trial and the characteristics of the investigational drug from an investigator and who signed the consent form or had a legal guardian or representative sign the consent form prior to the beginning of this clinical trial
Who cannot take part
- Patients who received Gliadel wafer implantation during surgery
- Participation in another clinical trial within 30 days prior to enrollment
- Patients with severe dysfunction of major organs (liver, kidney, bone marrow, lung, heart) as determined by the investigator
- Patients with concurrent malignancies other than glioblastoma or a history of malignancy within the past 5 years
- Patients with uncontrolled hypotension or hypertension
- Patients with serious infections as determined by the investigator, including sepsis, hepatitis A, B, or C
- Patients with autoimmune diseases involving the central nervous system (e.g., multiple sclerosis, myasthenia gravis, acute disseminated encephalomyelitis)
- Patients with a history of allergy to flucytosine (5-FC), its excipients, or 5-fluorouracil (5-FU)
- Any condition that, in the opinion of the investigator, would make the patient unsuitable for study participation
- Patients with recurrent glioblastoma. Known Dihydropyrimidine Dehydrogenase (DPD) deficiency Contraindications to contrast-enhanced MRI (e.g., patients with pacemakers or other reasons preventing MRI scans according to the study schedule)
- Patients with a Karnofsky Performance Scale (KPS) score < 50
- Pregnant or breastfeeding women, patients planning to become pregnant during the study period, or those unwilling to use appropriate contraception
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 70 years old?
Where in South Korea
- Bundang CHA Medical CenterSeongnam, South KoreaContact: Jaejoon Lim, M.D., Ph.DTaking people
About the trial
What the trial wants to find out
This is a phase I clinical trial evaluating the safety, tolerability, and maximum tolerated dose of MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell therapy expressing a suicide gene, in patients with newly diagnosed glioblastoma. The investigational product is administered intratumorally following surgical resection. This study aims to explore whether MSC11FCD can provide a targeted, localized treatment option during the postsurgical period, potentially addressing residual tumor cells and reducing early recurrence.
The group in the trial
- The investigational drug into the Intratumoral administrationOther group
The investigational drug in the amount of 1x10\^7, 3x10\^7cells per dose into the tumor or the tumor removal site using a syringe during surgery
Treatment: MSC11FCD
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Research of Suicide Gene Expressing Allogenic Bone Marrow Derived Mesenchymal Stem Cells(MSC11FCD) in Patients With Newly Diagnosed Glioblastoma
- Plain-language title
- Tests a stem cell gene therapy in adults with newly diagnosed glioblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07143812, who can take part
- Record updated
- 22 January 2026